BR0007360A - Composição de liberação controlada - Google Patents

Composição de liberação controlada

Info

Publication number
BR0007360A
BR0007360A BR0007360-1A BR0007360A BR0007360A BR 0007360 A BR0007360 A BR 0007360A BR 0007360 A BR0007360 A BR 0007360A BR 0007360 A BR0007360 A BR 0007360A
Authority
BR
Brazil
Prior art keywords
composition
release layer
uninterrupted
pharmaceutically active
active agent
Prior art date
Application number
BR0007360-1A
Other languages
English (en)
Inventor
Shun Y Lin
Lorraine L Wearley
Dilip J Gole
Gary W Posage
Paul K Wilkinson
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BR0007360A publication Critical patent/BR0007360A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO DE LIBERAçãO CONTROLADA"<D>. A presente invenção fornece uma composição compreendendo uma camada de liberação ininterrupta e uma camada de liberação rápida. A camada de liberação ininterrupta compreende um polímero solúvel em água e um primeiro agente ativo farmaceuticamente. A camada de liberação rápida compreende um agente de formação de matriz e um segundo agente ativo farmaceuticamente. Geralmente, a composição fornece liberação rápida e ininterrupta (controlada) de uma agente ativo farmaceuticamente por pelo menos 6 horas e preferivelmente por pelo menos 1 a 3 dias. A composição pode ser incorporada em uma forma de unidade de dosagem, tal como uma inserção vaginal. Métodos de preparar a composição são também fornecidos.
BR0007360-1A 1999-12-23 2000-12-21 Composição de liberação controlada BR0007360A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47182599A 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
BR0007360A true BR0007360A (pt) 2001-08-14

Family

ID=23873133

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007360-1A BR0007360A (pt) 1999-12-23 2000-12-21 Composição de liberação controlada

Country Status (14)

Country Link
US (1) US20050074490A1 (pt)
EP (1) EP1110541B1 (pt)
JP (1) JP2001278779A (pt)
KR (1) KR20010057581A (pt)
CN (1) CN1302604A (pt)
AR (1) AR027907A1 (pt)
AU (1) AU7251100A (pt)
BR (1) BR0007360A (pt)
CA (1) CA2329574A1 (pt)
CO (1) CO5251434A1 (pt)
DE (1) DE60015059T2 (pt)
ES (1) ES2228418T3 (pt)
HK (1) HK1037144A1 (pt)
MX (1) MXPA01000121A (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2366794A (en) * 2000-09-13 2002-03-20 Procter & Gamble Process for making a foam component
KR20030006788A (ko) * 2001-07-16 2003-01-23 이승진 치주질환 치료용 서방출성 고분자제제
US20060039974A1 (en) * 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7037522B2 (en) * 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
MY144021A (en) 2003-09-19 2011-07-29 Drugtech Corp Pharmaceutical delivery system
ES2308065T3 (es) * 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
ITFI20050215A1 (it) * 2005-10-13 2007-04-14 Valpharma Internat S P A Composizione nutrizionale a base di amminoacidi
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
US20070281008A1 (en) * 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
US20100322978A1 (en) * 2006-12-27 2010-12-23 Fujifilm Corporation Medical composition
US10548839B2 (en) * 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
WO2014116770A1 (en) * 2013-01-23 2014-07-31 Arx, Llc Production of unit dose constructs
RU2676288C2 (ru) 2013-12-31 2018-12-27 Джонсон энд Джонсон Консьюмер Инк. Способ формирования многослойного формованного пленочного продукта в один проход
AU2014374107B2 (en) * 2013-12-31 2020-02-06 Johnson & Johnson Consumer Inc. Process for forming a shaped film product
JP6588020B2 (ja) 2013-12-31 2019-10-09 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッド 多層賦形フィルムを形成するための方法
EP3525765A1 (en) * 2016-10-13 2019-08-21 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
JP6968184B2 (ja) * 2016-10-25 2021-11-17 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 速崩壊多層錠のための異なる密度の組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234091A (en) * 1955-07-08 1966-02-08 Ciba Geigy Corp Shaped medicaments and process for their manufacture
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
DE3212412C2 (de) * 1982-04-02 1986-01-02 Dr. Ruhland Nachf. GmbH, 8425 Neustadt Gewebeverklebbare kollagene Wundauflage
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4915953A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering acetaminophen or phenylpropanolamine
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5558880A (en) * 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5354558A (en) * 1992-09-10 1994-10-11 Mcneil-Pcc, Inc. Bioerodible contraceptive suppository
FI933979A0 (fi) * 1992-09-10 1993-09-10 Mcneil Ppc Inc Bioeroderbar anordning foer dosering av aktiva ingredienser
US5631023A (en) * 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
CA2134611C (en) * 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms
US5656283A (en) * 1995-06-08 1997-08-12 Ortho Pharmaceutical Corporation In-situ lyophilization of vaginal suppository in unit dose applicator and resultant product
BRPI9802144B1 (pt) * 1997-05-30 2017-03-28 Ezequiel Mayorga Jorge dispositivo osmótico multicapa aperfeiçoado
WO1999007342A1 (en) * 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives

Also Published As

Publication number Publication date
CO5251434A1 (es) 2003-02-28
DE60015059D1 (de) 2004-11-25
KR20010057581A (ko) 2001-07-04
ES2228418T3 (es) 2005-04-16
AR027907A1 (es) 2003-04-16
EP1110541B1 (en) 2004-10-20
DE60015059T2 (de) 2005-12-15
CN1302604A (zh) 2001-07-11
JP2001278779A (ja) 2001-10-10
US20050074490A1 (en) 2005-04-07
EP1110541A1 (en) 2001-06-27
AU7251100A (en) 2001-06-28
HK1037144A1 (en) 2003-04-24
MXPA01000121A (es) 2002-10-23
CA2329574A1 (en) 2001-06-23

Similar Documents

Publication Publication Date Title
BR0007360A (pt) Composição de liberação controlada
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
MY127797A (en) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
GB9908014D0 (en) Pharmaceutical compositions
GB2415142A (en) Porous matrix
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
IL135258A0 (en) Bioadhesive compositions and methods for topical administration of active agents
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
DE60023841D1 (de) Verfahren zur herstellung alkylierter salicylamide
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
FI971172A (fi) Menetelmä annosyksikköjen valmistamiseksi märkärakeistamalla
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
AU3850600A (en) Dalda analogs and their use
PL402549A1 (pl) Dopochwowa kompozycja farmaceutyczna i zastosowanie
BR9911648A (pt) Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo
ATE429925T1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
IL132853A (en) Composition for modulating the human sexual response
WO1998011887A3 (en) Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 12A E 13A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/20 (2006.01), A61K 9/00 (2006.01), A61K 9/2

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 12A, 13A, 14A, 15A, 16A, 17A, 18A E 19A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.